Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Waqqas Afif

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
Annals of Internal Medicine|November 4, 2024
In active ulcerative colitis, risankizumab induced and maintained remissionAlessandro Pedicelli, Waqqas Afif
Gastroenterology|February 6, 2021
Ustekinumab for Ulcerative ColitisReena Khanna, Waqqas Afif
Gastroenterology Clinics of North America|August 26, 2017
Update on Therapeutic Drug Monitoring in Crohn's DiseaseValérie Heron, Waqqas Afif
Journal of Clinical Medicine|April 3, 2021
Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel DiseaseSophie Restellini, Waqqas Afif
Gastroenterology Clinics of North America|August 12, 2014
Risk of infections with biological agentsUri Kopylov, Waqqas Afif
Gastroenterology|April 7, 2017
Ustekinumab for Crohn's DiseaseReena Khanna, Waqqas Afif
The Medical Clinics of North America|December 1, 2009
Safety profile of IBD therapeutics: infectious risksWaqqas Afif, Edward V Loftus
Gastroenterology Clinics of North America|November 17, 2009
Safety profile of IBD therapeutics: infectious risksWaqqas Afif, Edward V Loftus
Annals of Internal Medicine|July 3, 2023
In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse eventsReem Al-Jabri, Waqqas Afif
Inflammatory Bowel Diseases|May 23, 2018
Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel DiseaseSophie Restellini, Reena Khanna, Waqqas Afif
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
Annals of Internal Medicine|November 4, 2024
In active ulcerative colitis, risankizumab induced and maintained remissionAlessandro Pedicelli, Waqqas Afif
Gastroenterology|February 6, 2021
Ustekinumab for Ulcerative ColitisReena Khanna, Waqqas Afif
Gastroenterology Clinics of North America|August 26, 2017
Update on Therapeutic Drug Monitoring in Crohn's DiseaseValérie Heron, Waqqas Afif
Journal of Clinical Medicine|April 3, 2021
Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel DiseaseSophie Restellini, Waqqas Afif
Gastroenterology Clinics of North America|August 12, 2014
Risk of infections with biological agentsUri Kopylov, Waqqas Afif
Gastroenterology|April 7, 2017
Ustekinumab for Crohn's DiseaseReena Khanna, Waqqas Afif
The Medical Clinics of North America|December 1, 2009
Safety profile of IBD therapeutics: infectious risksWaqqas Afif, Edward V Loftus
Gastroenterology Clinics of North America|November 17, 2009
Safety profile of IBD therapeutics: infectious risksWaqqas Afif, Edward V Loftus
Annals of Internal Medicine|July 3, 2023
In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse eventsReem Al-Jabri, Waqqas Afif
Inflammatory Bowel Diseases|May 23, 2018
Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel DiseaseSophie Restellini, Reena Khanna, Waqqas Afif
Pageof 13